ArticlePloS one2016
Principal Component Analysis of Multimodal Neuromelanin MRI and Dopamine Transporter PET Data Provides a Specific Metric for the Nigral Dopaminergic Neuronal Density.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Diagnostic performance of neuromelanin-sensitive magnetic resonance imaging for patients with Parkinson's disease and factor analysis for its heterogeneity: a systematic review and meta-analysis.European radiology · 2021Pooled it
- Spectral presaturation with inversion recovery provides superior neuromelanin imaging for Parkinson's disease evaluation compared to magnetization transfer.Neuroradiology · 2026Article
- Longitudinal non-negative matrix factorization identifies the altered trajectory of motor symptoms in Parkinson's disease.NPJ Parkinson's disease · 2025Article
- Neuromelanin-sensitive MRI for mechanistic research and biomarker development in psychiatry.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Review
- Intense exercise increases dopamine transporter and neuromelanin concentrations in the substantia nigra in Parkinson's disease.NPJ Parkinson's disease · 2024Article
- Comparison of automated and manual quantification methods for neuromelanin-sensitive MRI in Parkinson's disease.Human brain mapping · 2024Article
- Two distinct degenerative types of nigrostriatal dopaminergic neuron in the early stage of parkinsonian disorders.Clinical parkinsonism & related disorders · 2024Article
- Probing midbrain dopamine function in pediatric obsessive-compulsive disorder via neuromelanin-sensitive magnetic resonance imaging.Molecular psychiatry · 2023Article
- Magnetic resonance imaging modalities aid in the differential diagnosis of atypical parkinsonian syndromes.Frontiers in neurology · 2023Review
- Iron- and Neuromelanin-Weighted Neuroimaging to Study Mitochondrial Dysfunction in Patients with Parkinson's Disease.International journal of molecular sciences · 2022Review
- [EJNMMI research · 2022Article
- Deep Learning-Based Neuromelanin MRI Changes of Isolated REM Sleep Behavior Disorder.Movement disorders : official journal of the Movement Disorder Society · 2022Article
- Influences of dopaminergic system dysfunction on late-life depression.Molecular psychiatry · 2022Review
- Longitudinal Changes in Neuromelanin MRI Signal in Parkinson's Disease: A Progression Marker.Movement disorders : official journal of the Movement Disorder Society · 2021Observational
- Reliability and Reproducibility of Neuromelanin-Sensitive Imaging of the Substantia Nigra: A Comparison of Three Different Sequences.Journal of magnetic resonance imaging : JMRI · 2021Article
- Is Generalized and Segmental Dystonia Accompanied by Impairments in the Dopaminergic System?Frontiers in neurology · 2021Article
- Neuromelanin imaging analyses of the substantia nigra in patients with Machado-Joseph disease.Neuroradiology · 2020Article
- A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein.Journal of Parkinson's disease · 2019Article
- Degree of dopaminergic degeneration measured byNeural regeneration research · 2018Article
- Neuromelanin detection by magnetic resonance imaging (MRI) and its promise as a biomarker for Parkinson's disease.NPJ Parkinson's disease · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The loss of dopaminergic (DA) neurons in the substantia nigra (SN) is a major pathophysiological feature of patients with Parkinson's disease (PD). As nigral DA neurons contain both neuromelanin (NM) and dopamine transporter (DAT), decreased intensities in both NM-sensitive MRI and DAT PET reflect decreased DA neuronal density. This study demonstrates that a more specific metric for the nigral DA neuronal density can be derived with multimodal MRI and PET. Participants were 11 clinically diagnosed PD patients and 10 age and gender matched healthy controls (HCs). Two quantities, the NM-related index (RNM) and the binding potential of the radiotracer [18F]FE-PE2I to DAT (BPND) in SN, were measured for each subject using MRI and PET, respectively. Principal component analysis (PCA) was applied to the multimodal data set to estimate principal components. One of the components, PCP, corresponds to a basis vector oriented in a direction where both BPND and RNM increase. The ability of BPND, RNM and PCP to discriminate between HC and PD groups was compared. Correlation analyses between the motor score of the unified Parkinson's disease rating scale and each metric were also performed. PCP, BPND and RNM for PD patients were significantly lower than those for HCs (F = 16.26, P<0.001; F = 6.05, P = 0.008; F = 7.31, P = 0.034, respectively). The differential diagnostic performance between the HC and PD groups as assessed by the area under the receiver-operating characteristic curve was best for PCP (0.94, 95% CI: 0.66-1.00). A significant negative correlation was found between the motor severity score and PCp (R = -0.70, P<0.001) and RNM (R = -0.52, P = 0.015), but not for BPND (R = -0.36, P = 0.110). PCA of multimodal NM-sensitive MRI and DAT PET data provides a metric for nigral DA neuronal density that will help illuminate the pathophysiology of PD in SN. Further studies are required to explore whether PCA is useful for other parkinsonian syndromes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.